About the Study

The Polycystic Kidney Disease Treatment Network (PKD-TN) has developed the HALT PKD clinical trials to evaluate certain FDA approved drugs that may be effective in slowing kidney growth in persons who have polycystic kidney disease. Seven centers across the United States are participating in the two trials.

Click here to read more.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player


Alan found out he had polycystic kidney disease around 5 years ago. He has generously agreed to share his story for us.

I had never heard of Polycystic Kidney Disease until about five years ago when an MRI revealed spots proliferating my kidneys and liver. I was 45 and the cause of my stomach trouble leading to these tests had nothing to do with the PKD they discovered. The big fear was cancer so when we reviewed an autopsy that had been performed on my father and found that he had PKD, it was actually a minor relief.

Click here to read more.

Nutritional Corner by Kelly Welsh, R.D, C.D.

this months recipe is Roasted Corn and Edamame Salad, click here to read more.

Featured Report

At the 2009 annual meeting of the Society of Nephrology, Dr. Vicent Torres from the Mayo Clinic HALT-PKD site presented baseline summary data of the HALT-PKD participants. Baseline data were collected prior to participants starting their study drug. At the time these results were summarized there were 269 participants in the Study A group whose blood pressure was to be controlled at the low rate, 275 Study A participants whose blood pressure was to be controlled at the standard rate and 485 participants enrolled in Study B. For details about the Study design click on the "About the Study" link within this website.

Half of the participants in both Study A and Study B were female. The average age for the Study A participants was 36 years and for the Study B participants it was 48 years. Mean Arterial pressure (nnHg) averaged in the low 90s for Study A and Study B participants. The average baseline estimated Glomular Filtration Rate was 86 (ml/min/1.73m2) for the Study A low participants and 87 for the Study A Standard participants. For the Study B participants the average baseline eGFR was 45. This difference is due to the fact that Study B participants had to have more advanced PK disease than those recruited for Study A.

The table below contains the average baseline values for select urine tests. The values in parentheses represent the range within which a majority of the particpants’ values reside.

Baseline characteristics Study A low (n=269) Study A standard (n=275) Study B (n=485)
U. volume (ml/24 hrs) 2536 1369, 3703) 2539 (1350, 3728) 2654 (1623, 3685)
U. sodium (mEq/24 hrs) 179 (98, 277) 178 (100, 256) 177 (95, 259)
U. albumin (mg/24 hrs) 21.6 (6.9, 36.3) 21.8 (7.3, 36.3) 27.2 (10.8, 43.6)
U. aldosterone (µg/24 hrs) 12.5 (4, 21) 14.6 (3, 26.2) 10.4 (2.6, 18.2)

In summary, baseline characteristics show no differences between study A arms. Moderate polyuria and high urine sodium excretions occurred in both studies, while higher albumin and lower aldosterone excretions occurred in study B compared to study A.